REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis
USA - NASDAQ:REGN - US75886F1075 - Common Stock
628 USD
-14.25 (-2.22%)
629.11 USD
+1.11 (+0.18%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year REGN was profitable.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
REGN's Return On Assets of 11.40% is amongst the best of the industry. REGN outperforms 94.19% of its industry peers.
With an excellent Return On Equity value of 14.79%, REGN belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
The Return On Invested Capital of REGN (8.69%) is better than 93.82% of its industry peers.
REGN had an Average Return On Invested Capital over the past 3 years of 12.44%. This is below the industry average of 15.38%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN has a better Profit Margin (32.13%) than 96.63% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
With an excellent Operating Margin value of 27.61%, REGN belongs to the best of the industry, outperforming 96.25% of the companies in the same industry.
REGN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 86.28%, REGN belongs to the best of the industry, outperforming 88.58% of the companies in the same industry.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
REGN has about the same amout of shares outstanding than it did 1 year ago.
REGN has less shares outstanding than it did 5 years ago.
REGN has a better debt/assets ratio than last year.
2.2 Solvency
REGN has an Altman-Z score of 6.74. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of REGN (6.74) is better than 77.72% of its industry peers.
The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.70, REGN belongs to the top of the industry, outperforming 95.13% of the companies in the same industry.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
REGN's Debt to Equity ratio of 0.09 is on the low side compared to the rest of the industry. REGN is outperformed by 63.11% of its industry peers.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 6.74 |
ROIC/WACC1.02
WACC8.49%
2.3 Liquidity
A Current Ratio of 4.06 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Current ratio (4.06) which is comparable to the rest of the industry.
A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
REGN has a Quick ratio of 3.51. This is comparable to the rest of the industry: REGN outperforms 43.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
REGN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 5.81% on average per year.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.26% yearly.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y5.81%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.95, which indicates a correct valuation of REGN.
Based on the Price/Earnings ratio, REGN is valued cheaply inside the industry as 96.82% of the companies are valued more expensively.
REGN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.03, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 14.14 indicates a correct valuation of REGN.
Based on the Price/Forward Earnings ratio, REGN is valued cheaper than 95.69% of the companies in the same industry.
REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.27.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.95 | ||
| Fwd PE | 14.14 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.32% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 95.69% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.15 | ||
| EV/EBITDA | 12.65 |
4.3 Compensation for Growth
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.06
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
REGN has a yearly dividend return of 0.54%, which is pretty low.
Compared to an average industry Dividend Yield of 89.85, REGN pays a better dividend. On top of this REGN pays more dividend than 98.31% of the companies listed in the same industry.
With a Dividend Yield of 0.54, REGN pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
628
-14.25 (-2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change0.19%
Ins Owners1.89%
Ins Owner Change0.18%
Market Cap66.56B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target747.8 (19.08%)
Short Float %2.87%
Short Ratio2.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)0.38%
PT rev (3m)-0.51%
EPS NQ rev (1m)-0.78%
EPS NQ rev (3m)3.7%
EPS NY rev (1m)0.53%
EPS NY rev (3m)10.86%
Revenue NQ rev (1m)0.55%
Revenue NQ rev (3m)4.52%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)3.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.95 | ||
| Fwd PE | 14.14 | ||
| P/S | 4.67 | ||
| P/FCF | 17.15 | ||
| P/OCF | 13.13 | ||
| P/B | 2.15 | ||
| P/tB | 2.25 | ||
| EV/EBITDA | 12.65 |
EPS(TTM)45.01
EY7.17%
EPS(NY)44.42
Fwd EY7.07%
FCF(TTM)36.62
FCFY5.83%
OCF(TTM)47.84
OCFY7.62%
SpS134.43
BVpS292.08
TBVpS279.05
PEG (NY)N/A
PEG (5Y)1.06
Graham Number543.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 6.74 |
F-Score5
WACC8.49%
ROIC/WACC1.02
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y5.81%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.26%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y7.36%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -6.32% in the next year.